Telmisartan vs. other antihypertensives on cardiometabolic and vascular outcomes in diabetic hypertension: A randomised trial - PubMed
4 hours ago
- #Insulin Resistance
- #Antihypertensives
- #Endothelial Function
- Telmisartan significantly improved insulin sensitivity in patients with type 2 diabetes and hypertension compared to other antihypertensives (amlodipine, cilnidipine, ramipril).
- HOMA-IR decreased more in the telmisartan group (from 4.1 to 1.79) than in the comparator group (from 3.9 to 3.45), indicating reduced insulin resistance.
- Endothelin-1 (ET-1) levels decreased similarly in both groups, suggesting comparable effects on endothelial function over the 12-week period.
- Telmisartan may offer additional metabolic benefits beyond blood pressure control, potentially lowering diabetes-related vascular complications.